Vibostolimab is a humanized IgG1 mAb, and it represents another anti-TIGIT compound currently in phase II of clinical trials in patients with advanced NSCLC and melanoma in combination with anti-PD-1 pembrolizumab [122], while domvanalimab is another humanized IgG1 anti-TIGIT antibody that in preclinical studies improved T cell functionality when used alone or in combinations with PD-1 blockade. Here, TIGIT is linked to melanoma.